One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences' total funding to date to over €20 […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!